Adverse events135

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

101 to 120 of 135

Type	Event	Organ system	Group	Affected	At risk
serious	Abdominal Pain	Gastrointestinal disorders	Abaloparatide Transdermal (50 mcg)	0	50
serious	Abdominal Pain	Gastrointestinal disorders	Abaloparatide Transdermal (100 mcg)	0	51
serious	Abdominal Pain	Gastrointestinal disorders	Abaloparatide Transdermal (150 mcg)	0	47
serious	Abdominal Pain	Gastrointestinal disorders	Abaloparatide Injection (80 mcg)	1	51
serious	Abdominal Pain	Gastrointestinal disorders	Abaloparatide Transdermal Placebo (0 mcg)	0	50
serious	Colitis	Gastrointestinal disorders	Abaloparatide Transdermal (50 mcg)	0	50
serious	Colitis	Gastrointestinal disorders	Abaloparatide Transdermal (100 mcg)	0	51
serious	Colitis	Gastrointestinal disorders	Abaloparatide Transdermal (150 mcg)	1	47
serious	Colitis	Gastrointestinal disorders	Abaloparatide Injection (80 mcg)	0	51
serious	Colitis	Gastrointestinal disorders	Abaloparatide Transdermal Placebo (0 mcg)	0	50
serious	Radius fracture	Injury, poisoning and procedural complications	Abaloparatide Transdermal (50 mcg)	0	50
serious	Radius fracture	Injury, poisoning and procedural complications	Abaloparatide Transdermal (100 mcg)	1	51
serious	Radius fracture	Injury, poisoning and procedural complications	Abaloparatide Transdermal (150 mcg)	0	47
serious	Radius fracture	Injury, poisoning and procedural complications	Abaloparatide Injection (80 mcg)	0	51
serious	Radius fracture	Injury, poisoning and procedural complications	Abaloparatide Transdermal Placebo (0 mcg)	0	50
serious	Osteoarthritis	Musculoskeletal and connective tissue disorders	Abaloparatide Transdermal (50 mcg)	0	50
serious	Osteoarthritis	Musculoskeletal and connective tissue disorders	Abaloparatide Transdermal (100 mcg)	0	51
serious	Osteoarthritis	Musculoskeletal and connective tissue disorders	Abaloparatide Transdermal (150 mcg)	1	47
serious	Osteoarthritis	Musculoskeletal and connective tissue disorders	Abaloparatide Injection (80 mcg)	1	51
serious	Osteoarthritis	Musculoskeletal and connective tissue disorders	Abaloparatide Transdermal Placebo (0 mcg)	0	50

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01674621/events?page=6

API reference For AI assistants